Strategic partnerships Viralgen actively forms collaborations with biotechnology players (Elaaj Bio, Apertura Gene Therapy, Trogenix, Axovia Therapeutics), highlighting a target to expand R&D and manufacturing partnerships for rAAV gene therapies. This pattern indicates sales opportunities in co-development, process optimization, and scalable manufacturing services.

AAV manufacturing leadership Anchored by a GMP-certified facility in San Sebastian and a robust suspension platform for AAV production, Viralgen positions itself as a premier CDMO for large-scale manufacturing, fill-finish, and QC—an attractive target for gene therapy programs seeking reliable, end-to-end production support.

Therapy diversification Active development efforts span prion disease gene therapy and collaboration with Broad Institute and Harvard labs, signaling a willingness to engage across rare and unmet medical needs. This opens sales doors for custom AAV vectors, regulatory support, and translational services for niche indications.

Technology and data Adoption of diverse tech stack including MATLAB, Power BI, AutoCAD, SAP, Azure and SQL Server suggests mature data, project management, and manufacturing workflows. This creates cross-sell opportunities for digitalization projects, data analytics collaboration, and integrated ERP/quality systems enhancements for clients.

Financial and market fit With revenue in the lower-mid tens of millions and a headcount appropriate for specialty CDMOs, Viralgen targets mid-sized gene therapy programs and partnerships with peers in the space, where they can compete on speed, GMP quality, and program breadth to win mid-market deals.